As we have previously reported, research has shown that several incretin mimetic pharmaceuticals may cause substantial injury in Type II diabetes patients. Incretin mimetic drugs help regulate blood sugar by stimulating insulin production by the pancreas.

 The April 8, 2013, edition of the Journal of the American Medical Association Internal Medicine (“JAMA”) published a study involving incretin mimetics, including Januvia and Byetta. The study reviewed administrative databases in the United States from 2005 until 2008, and concluded that there were “increased odds of hospitalization for acute pancreatitis” among uses of Januvia and Byetta.” The safety of these incretin mimetics has been the subject of recent studies and evaluations from the medical community and the Food and Drug Administration (“FDA”).

If you feel you have experienced any side-effects from taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Byetta, Januvia/Janumet or Victoza manufacturers.